{"id":402254,"date":"2020-12-17T15:04:25","date_gmt":"2020-12-17T20:04:25","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=402254"},"modified":"2020-12-17T15:04:25","modified_gmt":"2020-12-17T20:04:25","slug":"covid-19-medincell-presents-positive-first-results-from-the-clinical-trial-aiming-at-validating-the-safety-of-continuous-administration-of-ivermectin","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/covid-19-medincell-presents-positive-first-results-from-the-clinical-trial-aiming-at-validating-the-safety-of-continuous-administration-of-ivermectin\/","title":{"rendered":"Covid-19: MedinCell Presents Positive First Results From the Clinical Trial Aiming at Validating the Safety of Continuous Administration of Ivermectin"},"content":{"rendered":"<p>        <!--body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p><b>Covid-19: MedinCell Presents Positive First Results From the Clinical Trial Aiming at Validating the Safety of Continuous Administration of Ivermectin<\/b><\/p>\n<p>MONTPELLIER, France&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nMedinCell (Paris:MEDCL):\n<\/p>\n<p>\nStudy\u2019s first results presented at the international <i>\u201cCollaborative Workshop \u2013 Ivermectin against Covid-19\u201d<\/i> held on December 15, 16 and 17 at the initiative of MedinCell.\n<\/p>\n<p>\nNo side effects observed with the first two doses in the study, which includes a total of three doses.\n<\/p>\n<p>\nA first long-acting injectable formulation is ready to enter regulatory development.\n<\/p>\n<p><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Finvest.medincell.com%2F%23news&amp;esheet=52350800&amp;newsitemid=20201217006045&amp;lan=en-US&amp;anchor=Access+the+complete+press+release.&amp;index=1&amp;md5=9bf337d3912cbc63fa59f43c09ee57f6\">Access the complete press release.<\/a><\/p>\n<p><b>About MedinCell <\/b><\/p>\n<p>\nMedinCell is a clinical stage pharmaceutical company that develops a portfolio of long-acting injectable products in various therapeutic areas by combining its proprietary BEPO<sup>\u00ae<\/sup> technology with active ingredients already known and marketed. Through the controlled and extended release of the active pharmaceutical ingredient, MedinCell makes medical treatments more efficient, particularly thanks to improved compliance, i.e. compliance with medical prescriptions, and to a significant reduction in the quantity of medication required as part of a one-off or chronic treatment. The BEPO<sup>\u00ae<\/sup> technology makes it possible to control and guarantee the regular delivery of a drug at the optimal therapeutic dose for several days, weeks or months starting from the subcutaneous or local injection of a simple deposit of a few millimeters, fully bioresorbable. Based in Montpellier, MedinCell currently employs more than 130 people representing over 25 different nationalities.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201217006045r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20201217006045\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20201217006045\/en\/<\/a><\/span><\/p>\n<p>\nMedinCell<br \/>\n<br \/>David Heuz\u00e9<br \/>\n<br \/>Communication leader<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:david.heuze@medincell.com\">david.heuze@medincell.com<br \/>\n<\/a><br \/>+33 (0)6 83 25 21 86\n<\/p>\n<p>\nNewCap<br \/>\n<br \/>Mathilde Bohin \/ Louis-Victor Delouvrier<br \/>\n<br \/>Investor relations<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:medincell@newcap.eu\">medincell@newcap.eu<br \/>\n<\/a><br \/>+33 (0)1 44 71 98 53\n<\/p>\n<p>\nNewCap<br \/>\n<br \/>Nicolas Merigeau<br \/>\n<br \/>Media relations<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:medincell@newcap.eu\">medincell@newcap.eu<br \/>\n<\/a><br \/>+33 (0)1 44 71 94 98\n<\/p>\n<p><b>KEYWORDS:<\/b> France Europe<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Health Infectious Diseases Clinical Trials Research Science Pharmaceutical Biotechnology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\" \/>\n","protected":false},"excerpt":{"rendered":"<p>Covid-19: MedinCell Presents Positive First Results From the Clinical Trial Aiming at Validating the Safety of Continuous Administration of Ivermectin MONTPELLIER, France&#8211;(BUSINESS WIRE)&#8211; MedinCell (Paris:MEDCL): Study\u2019s first results presented at the international \u201cCollaborative Workshop \u2013 Ivermectin against Covid-19\u201d held on December 15, 16 and 17 at the initiative of MedinCell. No side effects observed with the first two doses in the study, which includes a total of three doses. A first long-acting injectable formulation is ready to enter regulatory development. Access the complete press release. About MedinCell MedinCell is a clinical stage pharmaceutical company that develops a portfolio of long-acting injectable products in various therapeutic areas by combining its proprietary BEPO\u00ae technology with active ingredients already known and marketed. Through &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/covid-19-medincell-presents-positive-first-results-from-the-clinical-trial-aiming-at-validating-the-safety-of-continuous-administration-of-ivermectin\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Covid-19: MedinCell Presents Positive First Results From the Clinical Trial Aiming at Validating the Safety of Continuous Administration of Ivermectin&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-402254","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Covid-19: MedinCell Presents Positive First Results From the Clinical Trial Aiming at Validating the Safety of Continuous Administration of Ivermectin - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/covid-19-medincell-presents-positive-first-results-from-the-clinical-trial-aiming-at-validating-the-safety-of-continuous-administration-of-ivermectin\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Covid-19: MedinCell Presents Positive First Results From the Clinical Trial Aiming at Validating the Safety of Continuous Administration of Ivermectin - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Covid-19: MedinCell Presents Positive First Results From the Clinical Trial Aiming at Validating the Safety of Continuous Administration of Ivermectin MONTPELLIER, France&#8211;(BUSINESS WIRE)&#8211; MedinCell (Paris:MEDCL): Study\u2019s first results presented at the international \u201cCollaborative Workshop \u2013 Ivermectin against Covid-19\u201d held on December 15, 16 and 17 at the initiative of MedinCell. No side effects observed with the first two doses in the study, which includes a total of three doses. A first long-acting injectable formulation is ready to enter regulatory development. Access the complete press release. About MedinCell MedinCell is a clinical stage pharmaceutical company that develops a portfolio of long-acting injectable products in various therapeutic areas by combining its proprietary BEPO\u00ae technology with active ingredients already known and marketed. Through &hellip; Continue reading &quot;Covid-19: MedinCell Presents Positive First Results From the Clinical Trial Aiming at Validating the Safety of Continuous Administration of Ivermectin&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/covid-19-medincell-presents-positive-first-results-from-the-clinical-trial-aiming-at-validating-the-safety-of-continuous-administration-of-ivermectin\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-17T20:04:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201217006045r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/covid-19-medincell-presents-positive-first-results-from-the-clinical-trial-aiming-at-validating-the-safety-of-continuous-administration-of-ivermectin\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/covid-19-medincell-presents-positive-first-results-from-the-clinical-trial-aiming-at-validating-the-safety-of-continuous-administration-of-ivermectin\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Covid-19: MedinCell Presents Positive First Results From the Clinical Trial Aiming at Validating the Safety of Continuous Administration of Ivermectin\",\"datePublished\":\"2020-12-17T20:04:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/covid-19-medincell-presents-positive-first-results-from-the-clinical-trial-aiming-at-validating-the-safety-of-continuous-administration-of-ivermectin\\\/\"},\"wordCount\":298,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/covid-19-medincell-presents-positive-first-results-from-the-clinical-trial-aiming-at-validating-the-safety-of-continuous-administration-of-ivermectin\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201217006045r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/covid-19-medincell-presents-positive-first-results-from-the-clinical-trial-aiming-at-validating-the-safety-of-continuous-administration-of-ivermectin\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/covid-19-medincell-presents-positive-first-results-from-the-clinical-trial-aiming-at-validating-the-safety-of-continuous-administration-of-ivermectin\\\/\",\"name\":\"Covid-19: MedinCell Presents Positive First Results From the Clinical Trial Aiming at Validating the Safety of Continuous Administration of Ivermectin - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/covid-19-medincell-presents-positive-first-results-from-the-clinical-trial-aiming-at-validating-the-safety-of-continuous-administration-of-ivermectin\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/covid-19-medincell-presents-positive-first-results-from-the-clinical-trial-aiming-at-validating-the-safety-of-continuous-administration-of-ivermectin\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201217006045r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2020-12-17T20:04:25+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/covid-19-medincell-presents-positive-first-results-from-the-clinical-trial-aiming-at-validating-the-safety-of-continuous-administration-of-ivermectin\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/covid-19-medincell-presents-positive-first-results-from-the-clinical-trial-aiming-at-validating-the-safety-of-continuous-administration-of-ivermectin\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/covid-19-medincell-presents-positive-first-results-from-the-clinical-trial-aiming-at-validating-the-safety-of-continuous-administration-of-ivermectin\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201217006045r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201217006045r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/covid-19-medincell-presents-positive-first-results-from-the-clinical-trial-aiming-at-validating-the-safety-of-continuous-administration-of-ivermectin\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Covid-19: MedinCell Presents Positive First Results From the Clinical Trial Aiming at Validating the Safety of Continuous Administration of Ivermectin\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Covid-19: MedinCell Presents Positive First Results From the Clinical Trial Aiming at Validating the Safety of Continuous Administration of Ivermectin - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/covid-19-medincell-presents-positive-first-results-from-the-clinical-trial-aiming-at-validating-the-safety-of-continuous-administration-of-ivermectin\/","og_locale":"en_US","og_type":"article","og_title":"Covid-19: MedinCell Presents Positive First Results From the Clinical Trial Aiming at Validating the Safety of Continuous Administration of Ivermectin - Market Newsdesk","og_description":"Covid-19: MedinCell Presents Positive First Results From the Clinical Trial Aiming at Validating the Safety of Continuous Administration of Ivermectin MONTPELLIER, France&#8211;(BUSINESS WIRE)&#8211; MedinCell (Paris:MEDCL): Study\u2019s first results presented at the international \u201cCollaborative Workshop \u2013 Ivermectin against Covid-19\u201d held on December 15, 16 and 17 at the initiative of MedinCell. No side effects observed with the first two doses in the study, which includes a total of three doses. A first long-acting injectable formulation is ready to enter regulatory development. Access the complete press release. About MedinCell MedinCell is a clinical stage pharmaceutical company that develops a portfolio of long-acting injectable products in various therapeutic areas by combining its proprietary BEPO\u00ae technology with active ingredients already known and marketed. Through &hellip; Continue reading \"Covid-19: MedinCell Presents Positive First Results From the Clinical Trial Aiming at Validating the Safety of Continuous Administration of Ivermectin\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/covid-19-medincell-presents-positive-first-results-from-the-clinical-trial-aiming-at-validating-the-safety-of-continuous-administration-of-ivermectin\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-17T20:04:25+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201217006045r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/covid-19-medincell-presents-positive-first-results-from-the-clinical-trial-aiming-at-validating-the-safety-of-continuous-administration-of-ivermectin\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/covid-19-medincell-presents-positive-first-results-from-the-clinical-trial-aiming-at-validating-the-safety-of-continuous-administration-of-ivermectin\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Covid-19: MedinCell Presents Positive First Results From the Clinical Trial Aiming at Validating the Safety of Continuous Administration of Ivermectin","datePublished":"2020-12-17T20:04:25+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/covid-19-medincell-presents-positive-first-results-from-the-clinical-trial-aiming-at-validating-the-safety-of-continuous-administration-of-ivermectin\/"},"wordCount":298,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/covid-19-medincell-presents-positive-first-results-from-the-clinical-trial-aiming-at-validating-the-safety-of-continuous-administration-of-ivermectin\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201217006045r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/covid-19-medincell-presents-positive-first-results-from-the-clinical-trial-aiming-at-validating-the-safety-of-continuous-administration-of-ivermectin\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/covid-19-medincell-presents-positive-first-results-from-the-clinical-trial-aiming-at-validating-the-safety-of-continuous-administration-of-ivermectin\/","name":"Covid-19: MedinCell Presents Positive First Results From the Clinical Trial Aiming at Validating the Safety of Continuous Administration of Ivermectin - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/covid-19-medincell-presents-positive-first-results-from-the-clinical-trial-aiming-at-validating-the-safety-of-continuous-administration-of-ivermectin\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/covid-19-medincell-presents-positive-first-results-from-the-clinical-trial-aiming-at-validating-the-safety-of-continuous-administration-of-ivermectin\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201217006045r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2020-12-17T20:04:25+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/covid-19-medincell-presents-positive-first-results-from-the-clinical-trial-aiming-at-validating-the-safety-of-continuous-administration-of-ivermectin\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/covid-19-medincell-presents-positive-first-results-from-the-clinical-trial-aiming-at-validating-the-safety-of-continuous-administration-of-ivermectin\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/covid-19-medincell-presents-positive-first-results-from-the-clinical-trial-aiming-at-validating-the-safety-of-continuous-administration-of-ivermectin\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201217006045r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201217006045r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/covid-19-medincell-presents-positive-first-results-from-the-clinical-trial-aiming-at-validating-the-safety-of-continuous-administration-of-ivermectin\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Covid-19: MedinCell Presents Positive First Results From the Clinical Trial Aiming at Validating the Safety of Continuous Administration of Ivermectin"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/402254","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=402254"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/402254\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=402254"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=402254"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=402254"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}